Intrinsiqs

Is Protalix BioTherapeutics, Inc. overvalued?

Protalix BioTherapeutics, Inc. (PLX) looks undervalued — trading about 13% below its fair value.

Undervalued
Current price $2.69 Fair value $3.04
Price
$2.69
Fair value
$3.04
Current P/E
14.8
Normal P/E
16.7
Market cap
$216.7M
Dividend yield
0.0%
Return on equity
31.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares PLX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.MRK Merck & Co., Inc.RHHBY Roche Holding AGUNH UnitedHealth Group Incorporated